HUE040063T2 - Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével - Google Patents

Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével

Info

Publication number
HUE040063T2
HUE040063T2 HUE06795317A HUE06795317A HUE040063T2 HU E040063 T2 HUE040063 T2 HU E040063T2 HU E06795317 A HUE06795317 A HU E06795317A HU E06795317 A HUE06795317 A HU E06795317A HU E040063 T2 HUE040063 T2 HU E040063T2
Authority
HU
Hungary
Prior art keywords
bmp
inhibition
stem cells
tumor stem
tumorigenic potential
Prior art date
Application number
HUE06795317A
Other languages
English (en)
Inventor
Angelo Luigi Vescovi
Brent Allan Reynolds
Original Assignee
Stemgen S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S P A filed Critical Stemgen S P A
Publication of HUE040063T2 publication Critical patent/HUE040063T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HUE06795317A 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével HUE040063T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19

Publications (1)

Publication Number Publication Date
HUE040063T2 true HUE040063T2 (hu) 2019-02-28

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16171392A HUE042197T2 (hu) 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével
HUE06795317A HUE040063T2 (hu) 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE16171392A HUE042197T2 (hu) 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével

Country Status (13)

Country Link
US (2) US9220756B2 (hu)
EP (2) EP1904093B1 (hu)
JP (3) JP5189977B2 (hu)
KR (2) KR101338533B1 (hu)
AU (1) AU2006271308B2 (hu)
CA (2) CA2615491C (hu)
DK (2) DK3117833T3 (hu)
ES (2) ES2686093T3 (hu)
HR (1) HRP20181379T1 (hu)
HU (2) HUE042197T2 (hu)
NZ (2) NZ565172A (hu)
PL (2) PL3117833T3 (hu)
WO (1) WO2007010394A2 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3117833T3 (en) 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
US8361955B2 (en) 2008-02-13 2013-01-29 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
HUE057153T2 (hu) * 2015-09-17 2022-04-28 Histide Ag Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása
WO2017046219A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
PL3349776T3 (pl) * 2015-09-17 2021-08-02 Histide Ag Związek farmaceutyczny agonisty receptora czynnika wzrostu i inhibitora białka adhezyjnego do przekształcania komórki nowotworowej w komórkę nienowotworową i jego zastosowanie
SG10201913394SA (en) * 2015-09-17 2020-03-30 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
CN113597315A (zh) * 2018-12-28 2021-11-02 国立大学法人东京大学 用于治疗和预防神经胶质瘤的药剂、脑肿瘤恶性程度标志物、脑肿瘤预后标志物、确定脑肿瘤恶性程度和预后的方法以及抑制肿瘤增殖的抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
JPH07502514A (ja) * 1991-12-24 1995-03-16 アムラド・コーポレイション・リミテッド 腫瘍及び肉腫の処置方法
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
JPH10511840A (ja) * 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド 形態形成タンパク質特異細胞表面レセプターおよびその使用
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CA2253587C (en) 1996-05-09 2008-01-29 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay and apparatus for ligand development and multi-variable protein chemistry optimization
AU1616700A (en) * 1998-11-13 2000-06-05 Curis, Inc. Methods of alleviating cancer symptoms
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
US20030162700A1 (en) * 2000-03-03 2003-08-28 Shipham Kylie Ann-Maree Method of treatment
JP4620052B2 (ja) 2003-09-12 2011-01-26 ステムセル テクノロジーズ インコーポレーティッド 神経コロニー形成アッセイ法
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
AU2004296375B2 (en) * 2003-12-05 2011-11-03 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
US8410246B2 (en) * 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
WO2015050844A1 (en) * 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Also Published As

Publication number Publication date
PL3117833T3 (pl) 2019-06-28
JP2015057452A (ja) 2015-03-26
JP2012107063A (ja) 2012-06-07
DK1904093T3 (en) 2018-09-03
KR20080082595A (ko) 2008-09-11
AU2006271308B2 (en) 2012-12-20
CA2790675A1 (en) 2007-01-25
JP5891068B2 (ja) 2016-03-22
WO2007010394A3 (en) 2007-08-30
HUE042197T2 (hu) 2019-06-28
JP5189977B2 (ja) 2013-04-24
JP2009502771A (ja) 2009-01-29
WO2007010394A2 (en) 2007-01-25
CA2615491A1 (en) 2007-01-25
ES2686093T3 (es) 2018-10-16
PL1904093T3 (pl) 2018-12-31
EP3117833A1 (en) 2017-01-18
NZ598031A (en) 2013-11-29
US9220756B2 (en) 2015-12-29
EP1904093A2 (en) 2008-04-02
US9737589B2 (en) 2017-08-22
US20160228511A1 (en) 2016-08-11
KR20120125990A (ko) 2012-11-19
CA2615491C (en) 2016-11-29
KR101311061B1 (ko) 2013-09-25
KR101338533B1 (ko) 2013-12-12
EP3117833B1 (en) 2019-01-23
EP1904093B1 (en) 2018-06-13
CA2790675C (en) 2016-12-20
AU2006271308A1 (en) 2007-01-25
HRP20181379T1 (hr) 2018-11-16
ES2710601T3 (es) 2019-04-26
US20100167999A1 (en) 2010-07-01
NZ565172A (en) 2012-12-21
DK3117833T3 (en) 2019-03-18

Similar Documents

Publication Publication Date Title
HRP20181379T1 (hr) Inhibiranje tumorogenog potencijala tumorskih matičnih stanica s bmp-4
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
IL242282A0 (en) Enzyme Inhibiting Compounds
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
IL179020A0 (en) Compounds for enzyme inhibition
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL179812A0 (en) THE IMPORTANCE OF THE GENE HoxB13 FOR CANCER
ZA200707639B (en) Methods of decreasing calcification
GB2424881B (en) Halophenyl derivatives of bisalkylfluorene
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
HK1104235A1 (en) S-mirtazapine for the treatment of hot flush
WO2007014250A8 (en) Abl kinase inhibition
IL187449A0 (en) Variants at chr8q24.21 confer risk of cancer
EP1890761A4 (en) PROCESS FOR REINFORCING LIPOLYSIS
GB0517387D0 (en) Combinations for the treatment of cancer
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
GB0605685D0 (en) Inhibition of tumour growth
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB2426765B (en) The preparation of multipotent stem cells
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
EP1905445A4 (en) HUMBLER OF TUMOR GROWTH
GB0517386D0 (en) Combinations for the treatment of cancer